

Resource Summary Report

Generated by [dkNET](#) on Sep 1, 2026

KMS-12-BM

RRID:CVCL_1334

Type: Cell Line

Proper Citation

RRID:CVCL_1334

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1334

Proper Citation: RRID:CVCL_1334

Description: Cell line KMS-12-BM is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Plasma cell myeloma

Defining Citation: [PMID:2479409](#), [PMID:2519219](#), [PMID:2768132](#), [PMID:8695815](#), [PMID:9290701](#), [PMID:10936422](#), [PMID:11039672](#), [PMID:15215163](#), [PMID:16956823](#), [PMID:17171682](#), [PMID:17692805](#), [PMID:18647998](#), [PMID:18700954](#), [PMID:19306352](#), [PMID:21173094](#), [PMID:22460905](#), [PMID:22806891](#), [PMID:25485619](#), [PMID:25688540](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30285677](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:31978347](#), [PMID:32123307](#), [PMID:35839778](#)

Comments: Population: Japanese., Part of: MD Anderson Cell Lines Project., Part of: LL-100 blood cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: KMS-12-BM

Synonyms: KMS 12 BM, KMS-12BM, KMS12-BM, KMS12BM, KMS-12, KMS12, Kawasaki Medical School-12-Bone Marrow

Cross References: BTO:BTO_0006459, CLO:CLO_0009842, EFO:EFO_0006612, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770,

ArrayExpress:E-MTAB-3610, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, ArrayExpress:E-TABM-1088, BioSample:SAMN01821691, BioSample:SAMN03472933, BioSample:SAMN10988243, cancercellines:CVCL_1334, Cell_Model_Passport:SIDM01020, CGH-DB:28-1, CGH-DB:9141-4, ChEMBL-Cells:ChEMBL4295426, ChEMBL-Targets:ChEMBL4296455, CLS:300287, Cosmic:2081425, Cosmic:2367302, Cosmic-CLP:907281, DepMap:ACH-000380, DSMZ:ACC-551, DSMZCellDive:ACC-551, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:907281, GEO:GSM99382, GEO:GSM143346, GEO:GSM290295, GEO:GSM562812, GEO:GSM887221, GEO:GSM888295, GEO:GSM1374601, GEO:GSM1669994, IARC_TP53:21435, IZSLER:BS TCL 240, JCRB:JCRB0429, LiGeA:CCLE_244, LINCS_LDP:LCL-2043, PharmacDB:KMS12BM_763_2019, PRIDE:PXD030239, PRIDE:PXD030304, Progenetix:CVCL_1334, PubChem_Cell_line:CVCL_1334, Wikidata:Q54900168

ID: CVCL_1334

Record Creation Time: 20220427T220705+0000

Record Last Update: 20260829T234421+0000

Ratings and Alerts

No rating or validation information has been found for KMS-12-BM.

No alerts have been found for KMS-12-BM.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Tang A, et al. (2026) Targeting BCMA in multiple myeloma with a trifunctional NK cell engager. Cell reports. Medicine, 7(3), 102628.

Tiwari PK, et al. (2026) An orally active dual CBP/p300 degrader targets core dependencies of multiple myeloma. Cell reports, 45(6), 117464.

Ng HL, et al. (2026) BCR::ABL1-Induced Enhancer Reprogramming Uncovers Hypersensitivity of Ph+B-ALL Cells to Enhancer-Targeting Drugs. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(25), e17231.

Cardona-Benavides IJ, et al. (2025) Exploring the role of cyclin D1 in the pathogenesis of multiple myeloma beyond cell cycle regulation. Molecular oncology.

Heredia-Guerrero SC, et al. (2024) Functional Investigation of IGF1R Mutations in Multiple Myeloma. *Cancers*, 16(11).

Yamamoto T, et al. (2024) Increased CSN5 expression enhances the sensitivity to lenalidomide in multiple myeloma cells. *iScience*, 27(12), 111399.

Dupéré-Richer D, et al. (2024) KDM6A Regulates Immune Response Genes in Multiple Myeloma. *bioRxiv : the preprint server for biology*.

Shearer T, et al. (2024) Kinetics of Nirogacestat-Mediated Increases in B-cell Maturation Antigen on Plasma Cells Inform Therapeutic Combinations in Multiple Myeloma. *Cancer research communications*, 4(12), 3114.

Beltrán-Visiedo M, et al. (2023) Dinaciclib synergizes with BH3 mimetics targeting BCL-2 and BCL-XL in multiple myeloma cell lines partially dependent on MCL-1 and in plasma cells from patients. *Molecular oncology*, 17(12), 2507.

Vannam R, et al. (2021) Targeted degradation of the enhancer lysine acetyltransferases CBP and p300. *Cell chemical biology*, 28(4), 503.

Heider M, et al. (2021) The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma. *Molecular cell*, 81(6), 1170.

Rotolo A, et al. (2018) Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting. *Cancer cell*, 34(4), 596.

Lee KJ, et al. (2017) Chromothripsis in Treatment Resistance in Multiple Myeloma. *Genomics & informatics*, 15(3), 87.